Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.
It’s the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.
The new guidance introduces pivotal updates that help better refine diagnostic and therapeutic workflows. It also emphasizes an environment of highly individualized, technology-supported, and preventive diabetes care.